课件：抗凝治疗与出血风险.pptVIP

* * 除输血外，停止抗凝治疗也是医生可能采取的措施之一，但停止抗凝治疗可能带来更严重的后果。 这是一项包括4万余名患者的分析，患者均来自GRACE研究。所有患者中共506名接受至少一种抗凝治疗的患者在入院当天或入院后1天内发生了大出血事件， 并有部分患者因此停止抗血小板或抗凝治疗。 此图显示了这部分患者停止或继续抗血小板或抗凝治疗后，死亡率的比较，由图可见，不持续抗凝治疗的患者死亡率明显高于持续治疗者。 * * * * * * * Overall, 12% (593/4993) of patients assigned to enoxaparin received UFH and 4% (205/4985) of patients assigned to UFH received enoxaparin after randomization (crossovers). Analyses of the impact of this postrandomization crossover are complicated because it is an event that occurs after randomization and is further confounded by the knowledge of the treatment assignment. Overal